French study tracks Dupilumab's Real-World impact on severe nasal polyps
NCT ID NCT06393946
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 150 adults in France with severe chronic rhinosinusitis and nasal polyps who are already taking dupilumab (Dupixent®). Researchers will collect data on patient characteristics, disease history, and treatment patterns over two years. The goal is to see how the drug performs in everyday clinical practice, including changes in symptoms like nasal congestion and polyp size, as well as any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dupilumab (Dupixent®)
- What this could lead to
- If successful, this study could provide real-world evidence on how well dupilumab works for severe nasal polyps in routine care, helping doctors optimize treatment.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors. It only includes patients already prescribed dupilumab, limiting generalizability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site Number: 250.0001
Nantes, 44093, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.